Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its blockbuster semaglutide (GLP-1 RA)-based therapies, Wegovy for obesity and ...

Telehealth company Hims & Hers (HIMS) saw a 34% stock drop after Novo Nordisk (NVO) ended their relationship. Investors must decide if it's a buying opportunity or a warning sign for the industry.

Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Market Catalysts to explain why Novo pulled out and what it means for the future of Hims & Hers and telehealth in the GLP-1 space.

Novo Nordisk (NVO) says its novel obesity drug, amycretin, shows promising results with up to 24% of weight loss in a Phase 1/2 trial. Read more here.

Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes Novo Nordisk aims to collaborate with mobile app developers as well as pharmacies and telehealth providers.

Lone Star will sell its majority stake in Portugal’s Novo Banco SA to French banking group BPCE, earning the private equity firm a huge windfall from the bet it made on the sector’s recovery almost a ...

Telehealth companies Ro and LifeMD are promoting Novo Nordisk's weight loss drug Wegovy at a discount, marking a new chapter in GLP-1 wars.

Novo pressures GLP-1 compounders as FDA ban takes hold The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off versions that have ...

Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential milestone payments of up to $1 billion.

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the stock right now. Should you?

Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company currently is the leading player.